Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Kessel-Lo – page 119

1 979 clinical trials in Kessel-Lo, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Kessel-Lo at a glance
1 979
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 979 trials in Kessel-Lo

Open in trial search

Study on the Effectiveness and Safety of Ocrelizumab for Adults with Primary Progressive Multiple Sclerosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

Rheumatoid arthritis

Not recruiting

Study on Methotrexate and Glucocorticoid Combination for Early Rheumatoid Arthritis, with Optional Etanercept for Non-Responders

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Etanercept
  • Sponsor:UZ Leuven

Crohn's disease

Not recruiting

Study on the Effects of Ozanimod for Children with Moderate to Severe Crohn's Disease Not Responding to Usual Treatments

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Ozanimod
  • Sponsor:Celgene International II S.a.r.l.

Bladder cancer

Not recruiting

Study of Pembrolizumab and Enfortumab Vedotin with Surgery vs. Surgery Alone for Patients with Muscle-Invasive Bladder Cancer Who Cannot or Choose Not to Use Cisplatin

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Safety and Pharmacokinetics of Risdiplam in Infants with Spinal Muscular Atrophy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Risdiplam
  • Sponsor:F. Hoffmann-La Roche AG

Study on Atezolizumab for Patients with High-Risk Muscle-Invasive Bladder Cancer with Positive ctDNA After Surgery

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Alagille syndrome

Not recruiting

Long-term Study on the Safety and Effectiveness of Odevixibat for Patients with Alagille Syndrome

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Odevixibat
  • Sponsor:Ipsen Pharma

Study of Nivolumab and Relatlimab for Patients with Stage III-IV Melanoma After Surgery

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol Myers Squibb International Corporation

Study on Dapagliflozin for Patients with Severe Chronic Kidney Disease to Improve Kidney and Heart Health Outcomes

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dapagliflozin
  • Sponsor:Universitair Medisch Centrum Groningen

Study of Amivantamab, Lazertinib, and Drug Combination for Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer After Osimertinib Failure

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Multiple sclerosis+2

Not recruiting

Study on the Effects of a Higher Dose of Ocrelizumab for Adults with Relapsing Multiple Sclerosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Methylprednisolone
  • Sponsor:F. Hoffmann-La Roche AG

Study of Belumosudil and Prednisone for Patients Aged 12 and Older with Newly Diagnosed Chronic Graft Versus Host Disease

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Kessel-Lo

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical trials focusing on proton pump inhibitor (PPI) deprescribing strategies for patients with chronic usage patterns. This research explores alternative treatment approaches for common digestive conditions.

  • Functional Dyspepsia Management
  • Gastroesophageal Reflux Treatment
  • Heartburn Control Methods

The study evaluates various therapeutic approaches, including on-demand medication and alginate-based alternatives, to optimize treatment protocols for patients with digestive disorders.

02 Primary Care Innovation

Research examining optimal medication reduction strategies in primary care settings, with a focus on improving long-term patient outcomes and reducing unnecessary medication use.

  • Medication Optimization
  • Patient-Centered Care
  • Therapeutic Alternative Assessment

This initiative aims to establish evidence-based guidelines for discontinuing long-term medications when they may no longer be clinically indicated.

03 Treatment Comparison Studies

Comparative research evaluating the effectiveness of different deprescribing approaches in managing common gastrointestinal conditions.

  • Medication Withdrawal Strategies
  • Alternative Treatment Methods
  • Clinical Outcome Assessment

The research compares traditional dose reduction methods with newer therapeutic strategies to determine optimal treatment pathways.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.